Anzeige
Mehr »
Login
Mittwoch, 08.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Rio Tintos Muster: Erst die Investition, dann die Milliarden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ECUE | ISIN: CA37149M2040 | Ticker-Symbol: N8T
Tradegate
08.01.25
11:40 Uhr
0,143 Euro
+0,013
+9,62 %
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
GENERATIVE AI SOLUTIONS CORP Chart 1 Jahr
5-Tage-Chart
GENERATIVE AI SOLUTIONS CORP 5-Tage-Chart
RealtimeGeldBriefZeit
0,1430,15612:47
0,1430,16412:34
PR Newswire
61 Leser
Artikel bewerten:
(0)

GENERATIVE AI SOLUTIONS CORP.: Genai Announces Change Of Management And Appointment Of Patrick Gray As Ceo

Finanznachrichten News

VANCOUVER, BC, Jan. 6, 2025 /PRNewswire/ - Generative AI Solutions Corp. ("GenAI" or the "Company") (CSE: AICO) (OTCQB: AICOF) announces that Mr. Patrick Gray has been appointed Chief Executive Officer and a director of the Company, effective January 6, 2025.

Mr. Ryan Selby, the former CEO of the Company, has resigned as an officer and director concurrently with Mr. Gray's appointment. The Company sincerely thanks Mr. Selby for his contributions and wishes him the greatest success in his further endeavors.

"Mr. Gray is the right leader to move the Company through the next stages of its growth, and I am pleased he is in a position to take over and continue to steer the Company through its next strategic phase," said Mr. Selby.

Mr. Gray was the Chief Operating Officer of the Company from December 2023 until his appointment as CEO. Mr. Gray is the President and Founder of an IT service provider that specializes in software development, AI and Data Analytics, software implementation services, public sector automation platforms, and legal technology services. The company has extensive expertise in utilizing Artificial Intelligence (AI) and Machine Learning (ML) in expert services to enhance document and data management capabilities.

"I am looking forward to moving into the Chief Executive seat, taking advantage of market conditions to grow the Company's business and using my industry knowledge and contacts to diversify the Company's holdings and business lines to drive shareholder value" said Mr. Gray.

In connection with Mr. Selby's resignation from the Company, the board of directors has agreed to convert to common shares of the Company (the "Accrual Shares") $145,000 of accrued but unpaid fees owing to Mr. Selby in connection with his service as CEO (the "Accrual Payment"), and to further issue to Mr. Selby 4,000,000 common shares (the "Termination Shares") as a term of his resignation in accordance with his management services agreement. The Accrual Shares and the Termination Shares will be issued at a deemed price of $0.09 per common share, and will be subject to a four month hold. Mr. Selby will not be entitled to receive any Accrual Shares unless and until he ceases to be an insider of the Company.

On Behalf of the Board of Directors,?

Patrick Gray

CEO, Director, and Chairman of the Board of Directors

Generative AI Solutions Corp.
Toll-free North America: +1-833-879-7632?
Outside North America: +1-406-879-7632
[email protected]
www.genai-solutions.com

ABOUT GENERATIVE AI SOLUTIONS CORP.

GenAI is a pioneering artificial intelligence company focused on developing a vertically integrated AI solutions business through its proprietary MAI Cloud platform, with the development and commercialization of AI-powered tools and solutions for businesses and consumers across multiple industries. At GenAI, our mission is to harness the power of AI to create transformative products and services that benefit business and consumers across various sectors. Our team of talented AI professionals and engineers are dedicated to developing state-of-the-art AI-based solutions that have broad applicability and can be seamlessly integrated into diverse workflows. By leveraging our MAI Cloud platform and our expertise in machine learning, natural language processing, and data analytics, we build versatile high-performance tools that redefine efficiency, productivity, and user experience.

For more information on GenAI, please visit www.genai-solutions.com.

Forward-Looking Information and Statements

This news release contains "forward-looking statements" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements.

Generally, such forward-looking information or forward-looking statements can be identified by the use of forward looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved".

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to continue as a going concern; the Company's ability to continue to develop revenue generating applications; continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company; and Company's ability to continue to meet the requirements of listing of the CSE.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

SOURCE GENERATIVE AI SOLUTIONS CORP.

© 2025 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.